FDA says Pozen’s aspirin combo may need more data – msnbc.com

(Reuters) – U.S. health regulators informed Pozen Inc that they have come to a preliminary determination that the company’s experimental drug to prevent stomach ulcers related to aspirin use did not show bioequivalence with 325 mg aspirin, further …

Leave a Reply

Your email address will not be published. Required fields are marked *